44 related articles for article (PubMed ID: 36087253)
1. A passage-dependent network for estimating the
Yang Y; Zhang W; Wang X; Yang J; Cui Y; Song H; Li W; Li W; Wu L; Du Y; He Z; Shi J; Zhang J
Front Cell Dev Biol; 2023; 11():998666. PubMed ID: 36824368
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells.
Favaretto G; Rossi MN; Cuollo L; Laffranchi M; Cervelli M; Soriani A; Sozzani S; Santoni A; Antonangeli F
Cancer Immunol Immunother; 2024 May; 73(6):113. PubMed ID: 38693312
[TBL] [Abstract][Full Text] [Related]
3. Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X; Yu C; Zhou S; Zhang Y; Tian B; Bian Y; Wang W; Lin H; Wang LW
Aging (Albany NY); 2024 Feb; 16(3):2494-2516. PubMed ID: 38305770
[TBL] [Abstract][Full Text] [Related]
4. Identification of aneuploidy-related gene signature to predict survival in head and neck squamous cell carcinomas.
Liu Y; Yuan Y; Chen T; Xiao H; Zhang X; Zhang F
Aging (Albany NY); 2023 Nov; 15(22):13100-13117. PubMed ID: 37988195
[TBL] [Abstract][Full Text] [Related]
5. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Nakajima R; Zhao L; Zhou Y; Shirasawa M; Uchida A; Murakawa H; Fikriyanti M; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833320
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
Liu M; Liu H; Chen J
Oncol Rep; 2018 Mar; 39(3):901-911. PubMed ID: 29399694
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
8. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
10. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Chen L; Pan J
Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744
[TBL] [Abstract][Full Text] [Related]
11. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
12. Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors.
Chen W; Zhang W; Chen M; Yang C; Fang T; Wang H; Reid LM; He Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1053-1071. PubMed ID: 36087253
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
